Microsoft acquires health-care software company

Microsoft has acquired the assets of Global Care Solutions Ltd., a health-care software company in Bangkok, Thailand Global Care Solutions comprises a fully integrated hospital information system and Radiology RIS/PACS complete with image archiving, patient and bed management, laboratory, pharmacy, radiology, pathology, financial accounting, materials management and HR systems

Affymetrix and Illumina in war path again as fresh patent litigation on microarray patents

Illumina and Affymetrix have been in a patent battle since 2004. In its second wave of patent infringement litigation cas against illumina filed in UK, Germany and US, Affymetrix has targeted technology offered by Solexa, the company acquired by Illumina in January 2007, as well as all of Illumina’s BeadArray(TM) products. The new case is [...]

Online Drug Discovery Database Launch

Assay Depot is claiming to become an on-demand” drug discovery services. The company is has launched Internet marketplace for the pharmaceutical services industry. By acting as a single point of contact between drug researchers and research service providers, the Assay Depot dramatically improves the efficiency of drug discovery research and, ultimately, helps deliver better and [...]

Affymetrix launches Affymetrix University an education effort

Affymetrix  launched Affymetrix University, a series of courses that will be held throughout Europe and North America. Santa Clara-based Affymetrix  said the courses give biologists a better understanding of how to design their microarray experiments successfully with appropriate quality control, and how to apply statistical methods to interpret biological results more effectively. for more details [...]

Gene Logic sells in genomics division

It hardly a week I have wrote about acquisition and mergers , it seems the rain is noit going to stop any time soon, the latest one , to give away the home plate is Genelogic agreeing to sell its genomics division to India HQ Ocimum Biosolutions subject to the authorization of the transaction at [...]

Mergers Acquisitions Consolidation-Microarray Industry bubble in making- The days are numbered

Bioinformatics promise has already had its brush with plenty of resistance, not it seems the time for microarray industry with consolidation and acqusitions and megers announced almost every week. The slow adoption and too many fragmented with disparate standards has made the industry a victim of its own success. the new kid on the block [...]

Toxicogenomics can change face of clinical trials

“Genomics is only the start. Proteomics has been around for years and metabonomics is an up and coming important technology, both of which are complimentary to genomics. But still I think that genomics will be the most successful and most predictive of all these technologies.” Dr Phil Hewitt  Head of Toxicogenomics at Merck. Meanwhile Gene [...]

Microsoft life science

Well every one is writing about google and its foray into biology and life science, so what is going on with Other companies . Microsoft started its BioIT alliance During 2006 and guss what Bill Gates said during the launch “Advances in our understanding of the human genome promise to revolutionize medicine and open the [...]

Is the SBIR grant program is unfairly towards small biotech companies

28 patient organizations joined BIO in asking Congress to restore eligibility to venture-backed biotech companies to “help innovative research move forward in order to foster breakthrough cures.” Under the SBA’s new rules, companies with more than 50 percent of their backing from venture capital can’t compete for grants  Biotech industry calls on Congress to change [...]

Hocus Locus Spins out of University of Albany

Hocus Locus, a bioinformatics company which is part of the $225 million Gen*NY*Sis   Programe (Generating Employment through New York State Science) is located at the Center for Excellence in Cancer Genomics in University of Albany, it makes products to help small drug discovery companies speed up development of new drugs.